Ontology highlight
ABSTRACT:
Methods: This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received LdT (600?mg/day) for 24?weeks, Adefovir (ADV) was added if HBV DNA remained detectable at week 24, otherwise LdT was maintained to use until 104?weeks. HBV DNA, alanine amino transferase (ALT), hepatitis B surface antigen(HBsAg), creatinine kinase(CK), and estimated glomerular filtration rate (eGFR) were measured, safety was assessed.
Results: Eighty-eight patients (81%) had HBV-DNA undetectable at 24?weeks and maintained to receive LdT monotherapy until 104?weeks, whereas the other 20 patients had HBV-DNA detectable and ADV was used in combination. For all patients, 72% of patients reached ALT normalization at 24?weeks, which increased to 80% at 52?weeks and 104?weeks, respectively.. 81% of total patients had undetectable HBV-DNA at 24?weeks, 92% at 52?weeks, and 94% at 104?weeks. The HBsAg titre declined steadily from baseline to 104?weeks (3.62 vs. 2.98 log10 IU/mL, p?2, p?
Conclusions: LdT was well tolerated and effective, and 94% of patients achieved virological suppression after 104?weeks.
Trial registration: This study was registered in clinicaltrials.gov on January 31, 2012 and the ID No. was NCT01521975 .
SUBMITTER: Gan W
PROVIDER: S-EPMC7720458 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Gan Weiqiang W Li Jianguo J Zhang Chunlan C Chen Xuefu X Lin Chaoshuang C Gao Zhiliang Z
BMC infectious diseases 20201207 1
<h4>Background</h4>Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative.<h4>Methods</h4>This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received LdT (600 mg/day) for 24 weeks, Adefovir (ADV) was added if HBV DNA remained detectable at week 24, otherwise LdT was maintained to use until 104 weeks. HBV DNA, alanine amino transferase ...[more]